<DOC>
	<DOCNO>NCT00492921</DOCNO>
	<brief_summary>RATIONALE : High-dose cyclophosphamide may effective treatment acute graft-versus-host disease respond steroid therapy . PURPOSE : This phase II trial study side effect , best dose , well high-dose cyclophosphamide work treat patient acute graft-versus-host disease respond steroid therapy .</brief_summary>
	<brief_title>High-Dose Cyclophosphamide Treating Patients With Acute Graft-Versus-Host Disease That Did Not Respond Steroid Therapy</brief_title>
	<detailed_description>OBJECTIVES : - Determine maximum tolerate dose high-dose cyclophosphamide patient steroid refractory acute graft-versus-host disease . - Determine efficacy regimen 28 day post-treatment patient . OUTLINE : This dose-escalation study . Patients receive high-dose cyclophosphamide daily 1-4 day begin day 1 filgrastim ( G-CSF ) subcutaneously daily begin day 10 continue blood count recover . Cohorts 3-6 patient receive escalate dos high-dose cyclophosphamide maximum tolerate dose ( MTD ) determine . The MTD define dose precede 2 3 2 6 patient experience dose-limiting toxicity . After completion study treatment , patient follow weekly 4 week .</detailed_description>
	<mesh_term>Graft v Host Disease</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm acute graftversushost disease ( GVHD ) ≥ clinical grade II , steroid refractory Steroid refractory GVHD define GVHD progress ( increase grade ) despite 49 hour treatment methylprednisolone ≥ 2.0 mg/kg OR GVHD fail improve ( change grade stage ) despite 4 day treatment methylprednisolone ≥ 2.0 mg/kg Prior allogeneic hematopoietic stem cell transplantation use either bone marrow , peripheral blood stem cell , cord blood OR prior donor lymphocyte infusion require Evidence myeloid engraftment No chronic GVHD PATIENT CHARACTERISTICS : ECOG performance status ( PS ) 02 OR Karnofsky PS 60100 % ANC &gt; 500/mm³ Not pregnant nursing Fertile patient must use effective contraception Must geographically accessible No allergy intolerance cyclophosphamide mesna No HIV positivity No mechanical ventilation No active bleeding ( exclude gastrointestinal bleeding ) history hemorrhagic cystitis No uncontrolled illness include , limited , follow : Ongoing active infection Medical condition preclude patient stopping azoles ( e.g. , fluconazole , itraconazole , voriconazole ) adequate antifungal therapy cyclophosphamide administration Symptomatic congestive heart failure Unstable angina pectoris Psychiatric illness/social situation would preclude compliance PRIOR CONCURRENT THERAPY : See Disease Characteristics</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>June 2013</verification_date>
	<keyword>graft versus host disease</keyword>
</DOC>